Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
KalVista Pharma Stock (NASDAQ: KALV) stock price, news, charts, stock research, profile.
Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.740 | 0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-08-22 | Cantor Fitzgerald | Charles Duncan | Reiterates | OverweightOverweight | Maintains | - | 20.00 |
2023-07-10 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-04-21 | Needham | Serge Belanger | Reiterates | Buy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KALV | KalVista Pharma | 5.22% | 346.8M |
ZURA | Zura Bio | -3.37% | 287.7M |
MGNX | Macrogenics | 3.7% | 295.5M |
SPRY | ARS Pharmaceuticals | 4.17% | 358.4M |
HUMA | Humacyte | -0.7% | 293.8M |
You can purchase shares of KalVista Pharma (NASDAQ: KALV) through any online brokerage.
Other companies in KalVista Pharma’s space includes: Zura Bio (NASDAQ:ZURA), Macrogenics (NASDAQ:MGNX), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Precigen (NASDAQ:PGEN).
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on Friday, September 8, 2023. The analyst firm set a price target for 16.00 expecting KALV to rise to within 12 months (a possible 58.73% upside). 11 analyst firms have reported ratings in the last year.
The stock price for KalVista Pharma (NASDAQ: KALV) is $10.08 last updated Today at September 26, 2023 at 8:00 PM UTC.
There is no dividend information for KalVista Pharma.
KalVista Pharma’s Q2 earnings are confirmed for Thursday, December 7, 2023.
There is no upcoming split for KalVista Pharma.
KalVista Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
KalVista Pharma Stock (NASDAQ: KALV) stock price, news, charts, stock research, profile.
Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.740 | 0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-08-22 | Cantor Fitzgerald | Charles Duncan | Reiterates | OverweightOverweight | Maintains | - | 20.00 |
2023-07-10 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-04-21 | Needham | Serge Belanger | Reiterates | Buy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KALV | KalVista Pharma | 5.22% | 346.8M |
ZURA | Zura Bio | -3.37% | 287.7M |
MGNX | Macrogenics | 3.7% | 295.5M |
SPRY | ARS Pharmaceuticals | 4.17% | 358.4M |
HUMA | Humacyte | -0.7% | 293.8M |
You can purchase shares of KalVista Pharma (NASDAQ: KALV) through any online brokerage.
Other companies in KalVista Pharma’s space includes: Zura Bio (NASDAQ:ZURA), Macrogenics (NASDAQ:MGNX), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Precigen (NASDAQ:PGEN).
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on Friday, September 8, 2023. The analyst firm set a price target for 16.00 expecting KALV to rise to within 12 months (a possible 58.73% upside). 11 analyst firms have reported ratings in the last year.
The stock price for KalVista Pharma (NASDAQ: KALV) is $10.08 last updated Today at September 26, 2023 at 8:00 PM UTC.
There is no dividend information for KalVista Pharma.
KalVista Pharma’s Q2 earnings are confirmed for Thursday, December 7, 2023.
There is no upcoming split for KalVista Pharma.
KalVista Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
KalVista Pharma Stock (NASDAQ: KALV) stock price, news, charts, stock research, profile.
Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.740 | 0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-08-22 | Cantor Fitzgerald | Charles Duncan | Reiterates | OverweightOverweight | Maintains | - | 20.00 |
2023-07-10 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-04-21 | Needham | Serge Belanger | Reiterates | Buy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KALV | KalVista Pharma | 5.22% | 346.8M |
ZURA | Zura Bio | -3.37% | 287.7M |
MGNX | Macrogenics | 3.7% | 295.5M |
SPRY | ARS Pharmaceuticals | 4.17% | 358.4M |
HUMA | Humacyte | -0.7% | 293.8M |
You can purchase shares of KalVista Pharma (NASDAQ: KALV) through any online brokerage.
Other companies in KalVista Pharma’s space includes: Zura Bio (NASDAQ:ZURA), Macrogenics (NASDAQ:MGNX), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Precigen (NASDAQ:PGEN).
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on Friday, September 8, 2023. The analyst firm set a price target for 16.00 expecting KALV to rise to within 12 months (a possible 58.73% upside). 11 analyst firms have reported ratings in the last year.
The stock price for KalVista Pharma (NASDAQ: KALV) is $10.08 last updated Today at September 26, 2023 at 8:00 PM UTC.
There is no dividend information for KalVista Pharma.
KalVista Pharma’s Q2 earnings are confirmed for Thursday, December 7, 2023.
There is no upcoming split for KalVista Pharma.
KalVista Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
KalVista Pharma Stock (NASDAQ: KALV) stock price, news, charts, stock research, profile.
Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.740 | 0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-08-22 | Cantor Fitzgerald | Charles Duncan | Reiterates | OverweightOverweight | Maintains | - | 20.00 |
2023-07-10 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-04-21 | Needham | Serge Belanger | Reiterates | Buy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KALV | KalVista Pharma | 5.22% | 346.8M |
ZURA | Zura Bio | -3.37% | 287.7M |
MGNX | Macrogenics | 3.7% | 295.5M |
SPRY | ARS Pharmaceuticals | 4.17% | 358.4M |
HUMA | Humacyte | -0.7% | 293.8M |
You can purchase shares of KalVista Pharma (NASDAQ: KALV) through any online brokerage.
Other companies in KalVista Pharma’s space includes: Zura Bio (NASDAQ:ZURA), Macrogenics (NASDAQ:MGNX), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Precigen (NASDAQ:PGEN).
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on Friday, September 8, 2023. The analyst firm set a price target for 16.00 expecting KALV to rise to within 12 months (a possible 58.73% upside). 11 analyst firms have reported ratings in the last year.
The stock price for KalVista Pharma (NASDAQ: KALV) is $10.08 last updated Today at September 26, 2023 at 8:00 PM UTC.
There is no dividend information for KalVista Pharma.
KalVista Pharma’s Q2 earnings are confirmed for Thursday, December 7, 2023.
There is no upcoming split for KalVista Pharma.
KalVista Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
KalVista Pharma Stock (NASDAQ: KALV) stock price, news, charts, stock research, profile.
Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.740 | 0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-08-22 | Cantor Fitzgerald | Charles Duncan | Reiterates | OverweightOverweight | Maintains | - | 20.00 |
2023-07-10 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-04-21 | Needham | Serge Belanger | Reiterates | Buy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KALV | KalVista Pharma | 5.22% | 346.8M |
ZURA | Zura Bio | -3.37% | 287.7M |
MGNX | Macrogenics | 3.7% | 295.5M |
SPRY | ARS Pharmaceuticals | 4.17% | 358.4M |
HUMA | Humacyte | -0.7% | 293.8M |
You can purchase shares of KalVista Pharma (NASDAQ: KALV) through any online brokerage.
Other companies in KalVista Pharma’s space includes: Zura Bio (NASDAQ:ZURA), Macrogenics (NASDAQ:MGNX), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Precigen (NASDAQ:PGEN).
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on Friday, September 8, 2023. The analyst firm set a price target for 16.00 expecting KALV to rise to within 12 months (a possible 58.73% upside). 11 analyst firms have reported ratings in the last year.
The stock price for KalVista Pharma (NASDAQ: KALV) is $10.08 last updated Today at September 26, 2023 at 8:00 PM UTC.
There is no dividend information for KalVista Pharma.
KalVista Pharma’s Q2 earnings are confirmed for Thursday, December 7, 2023.
There is no upcoming split for KalVista Pharma.
KalVista Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
KalVista Pharma Stock (NASDAQ: KALV) stock price, news, charts, stock research, profile.
Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.740 | 0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-08-22 | Cantor Fitzgerald | Charles Duncan | Reiterates | OverweightOverweight | Maintains | - | 20.00 |
2023-07-10 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-04-21 | Needham | Serge Belanger | Reiterates | Buy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KALV | KalVista Pharma | 5.22% | 346.8M |
ZURA | Zura Bio | -3.37% | 287.7M |
MGNX | Macrogenics | 3.7% | 295.5M |
SPRY | ARS Pharmaceuticals | 4.17% | 358.4M |
HUMA | Humacyte | -0.7% | 293.8M |
You can purchase shares of KalVista Pharma (NASDAQ: KALV) through any online brokerage.
Other companies in KalVista Pharma’s space includes: Zura Bio (NASDAQ:ZURA), Macrogenics (NASDAQ:MGNX), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Precigen (NASDAQ:PGEN).
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on Friday, September 8, 2023. The analyst firm set a price target for 16.00 expecting KALV to rise to within 12 months (a possible 58.73% upside). 11 analyst firms have reported ratings in the last year.
The stock price for KalVista Pharma (NASDAQ: KALV) is $10.08 last updated Today at September 26, 2023 at 8:00 PM UTC.
There is no dividend information for KalVista Pharma.
KalVista Pharma’s Q2 earnings are confirmed for Thursday, December 7, 2023.
There is no upcoming split for KalVista Pharma.
KalVista Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
KalVista Pharma Stock (NASDAQ: KALV) stock price, news, charts, stock research, profile.
Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.740 | 0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-08-22 | Cantor Fitzgerald | Charles Duncan | Reiterates | OverweightOverweight | Maintains | - | 20.00 |
2023-07-10 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-04-21 | Needham | Serge Belanger | Reiterates | Buy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KALV | KalVista Pharma | 5.22% | 346.8M |
ZURA | Zura Bio | -3.37% | 287.7M |
MGNX | Macrogenics | 3.7% | 295.5M |
SPRY | ARS Pharmaceuticals | 4.17% | 358.4M |
HUMA | Humacyte | -0.7% | 293.8M |
You can purchase shares of KalVista Pharma (NASDAQ: KALV) through any online brokerage.
Other companies in KalVista Pharma’s space includes: Zura Bio (NASDAQ:ZURA), Macrogenics (NASDAQ:MGNX), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Precigen (NASDAQ:PGEN).
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on Friday, September 8, 2023. The analyst firm set a price target for 16.00 expecting KALV to rise to within 12 months (a possible 58.73% upside). 11 analyst firms have reported ratings in the last year.
The stock price for KalVista Pharma (NASDAQ: KALV) is $10.08 last updated Today at September 26, 2023 at 8:00 PM UTC.
There is no dividend information for KalVista Pharma.
KalVista Pharma’s Q2 earnings are confirmed for Thursday, December 7, 2023.
There is no upcoming split for KalVista Pharma.
KalVista Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
KalVista Pharma Stock (NASDAQ: KALV) stock price, news, charts, stock research, profile.
Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.740 | 0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-08-22 | Cantor Fitzgerald | Charles Duncan | Reiterates | OverweightOverweight | Maintains | - | 20.00 |
2023-07-10 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-04-21 | Needham | Serge Belanger | Reiterates | Buy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KALV | KalVista Pharma | 5.22% | 346.8M |
ZURA | Zura Bio | -3.37% | 287.7M |
MGNX | Macrogenics | 3.7% | 295.5M |
SPRY | ARS Pharmaceuticals | 4.17% | 358.4M |
HUMA | Humacyte | -0.7% | 293.8M |
You can purchase shares of KalVista Pharma (NASDAQ: KALV) through any online brokerage.
Other companies in KalVista Pharma’s space includes: Zura Bio (NASDAQ:ZURA), Macrogenics (NASDAQ:MGNX), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Precigen (NASDAQ:PGEN).
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on Friday, September 8, 2023. The analyst firm set a price target for 16.00 expecting KALV to rise to within 12 months (a possible 58.73% upside). 11 analyst firms have reported ratings in the last year.
The stock price for KalVista Pharma (NASDAQ: KALV) is $10.08 last updated Today at September 26, 2023 at 8:00 PM UTC.
There is no dividend information for KalVista Pharma.
KalVista Pharma’s Q2 earnings are confirmed for Thursday, December 7, 2023.
There is no upcoming split for KalVista Pharma.
KalVista Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
KalVista Pharma Stock (NASDAQ: KALV) stock price, news, charts, stock research, profile.
Open9.610 | Close10.080 |
Vol / Avg.359.113K / 209.909K | Mkt Cap346.787M |
Day Range9.610 - 10.320 | 52 Wk Range4.120 - 15.090 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.740 | 0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-08-22 | Cantor Fitzgerald | Charles Duncan | Reiterates | OverweightOverweight | Maintains | - | 20.00 |
2023-07-10 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 16.00 |
2023-04-21 | Needham | Serge Belanger | Reiterates | Buy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
KALV | KalVista Pharma | 5.22% | 346.8M |
ZURA | Zura Bio | -3.37% | 287.7M |
MGNX | Macrogenics | 3.7% | 295.5M |
SPRY | ARS Pharmaceuticals | 4.17% | 358.4M |
HUMA | Humacyte | -0.7% | 293.8M |
You can purchase shares of KalVista Pharma (NASDAQ: KALV) through any online brokerage.
Other companies in KalVista Pharma’s space includes: Zura Bio (NASDAQ:ZURA), Macrogenics (NASDAQ:MGNX), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Precigen (NASDAQ:PGEN).
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on Friday, September 8, 2023. The analyst firm set a price target for 16.00 expecting KALV to rise to within 12 months (a possible 58.73% upside). 11 analyst firms have reported ratings in the last year.
The stock price for KalVista Pharma (NASDAQ: KALV) is $10.08 last updated Today at September 26, 2023 at 8:00 PM UTC.
There is no dividend information for KalVista Pharma.
KalVista Pharma’s Q2 earnings are confirmed for Thursday, December 7, 2023.
There is no upcoming split for KalVista Pharma.
KalVista Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.